Quick Answer
Inhibikase Therapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2024.
Inhibikase Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | $0.00 -100.0% |
$260.5K +111.0% |
$123.4K -96.0% |
$3.10M +343.9% |
$698.5K |
| Revenue (ASC 606) | — | $0.00 -100.0% |
$260.5K +111.0% |
$123.4K -96.0% |
$3.10M +343.9% |
$698.5K |
| Net Income | -$48.26M -75.4% |
-$27.52M -44.6% |
-$19.03M -5.4% |
-$18.05M -22.1% |
-$14.79M -419.2% |
-$2.85M |
| Diluted EPS | -$0.49 +57.8% |
-$1.16 +63.3% |
-$3.16 +26.2% |
-$4.28 -428.4% |
-$0.81 | — |
| Total Assets | $181.20M +83.8% |
$98.60M +579.7% |
$14.51M -41.8% |
$24.94M -41.3% |
$42.47M +187.3% |
$14.78M |
| Stockholders Equity | $172.90M +82.3% |
$94.87M +764.2% |
$10.98M -47.8% |
$21.04M -45.2% |
$38.42M +292.6% |
$9.78M +317.9% |
| R&D Expense | $29.79M +73.1% |
$17.21M +26.4% |
$13.62M +13.2% |
$12.03M +6.0% |
$11.36M +1170.9% |
$893.8K |
| Operating Income | -$51.97M -81.8% |
-$28.59M -42.3% |
-$20.09M -10.8% |
-$18.13M -22.8% |
-$14.77M -423.9% |
-$2.82M |
| Shares Outstanding | 131.69M +89.9% |
69.36M +1021.2% |
6.19M +46.4% |
4.22M -83.2% |
25.16M +150.3% |
10.05M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2024 | $0.00 | -100.0% | — |
| Revenue (ASC 606) | September 30, 2024 | $0.00 | -100.0% | — |
| Net Income | September 30, 2025 | -$11.93M | -106.5% | -20.3% |
| Diluted EPS | September 30, 2025 | -$0.13 | +80.0% | -18.2% |
| Total Assets | September 30, 2025 | $79.59M | +1718.5% | -10.4% |
| Stockholders Equity | September 30, 2025 | $72.90M | +13839.1% | -8.9% |
| R&D Expense | September 30, 2025 | $7.65M | +82.6% | +45.1% |
| Operating Income | September 30, 2025 | -$12.77M | -119.1% | -17.9% |
| Shares Outstanding | September 30, 2025 | 74.81M | +902.2% | +0.4% |
- Inhibikase Therapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2024.
- Inhibikase Therapeutics, Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- Inhibikase Therapeutics, Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2024.
- Inhibikase Therapeutics, Inc. showed a decrease of -100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Inhibikase Therapeutics, Inc. reported Net Income of -$48.26 million for fiscal year 2025.
- Inhibikase Therapeutics, Inc. showed a decrease of -75.4% in Net Income compared to the prior fiscal year.
- Inhibikase Therapeutics, Inc. reported Diluted EPS of $0.49 per share (loss) for fiscal year 2025.
- Inhibikase Therapeutics, Inc. showed an increase of +57.8% in Diluted EPS compared to the prior fiscal year.
- Inhibikase Therapeutics, Inc. reported Total Assets of $181.20 million for fiscal year 2025.
- Inhibikase Therapeutics, Inc. showed an increase of +83.8% in Total Assets compared to the prior fiscal year.
- Inhibikase Therapeutics, Inc. reported Stockholders Equity of $172.90 million for fiscal year 2025.
- Inhibikase Therapeutics, Inc. showed an increase of +82.3% in Stockholders Equity compared to the prior fiscal year.
- Inhibikase Therapeutics, Inc. reported R&D Expense of $29.79 million for fiscal year 2025.
- Inhibikase Therapeutics, Inc. showed an increase of +73.1% in R&D Expense compared to the prior fiscal year.
- Inhibikase Therapeutics, Inc. reported Operating Income of -$51.97 million for fiscal year 2025.
- Inhibikase Therapeutics, Inc. showed a decrease of -81.8% in Operating Income compared to the prior fiscal year.
- Inhibikase Therapeutics, Inc. reported Shares Outstanding of 131.69 million shares for fiscal year 2025.
- Inhibikase Therapeutics, Inc. showed an increase of +89.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: